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We reviewed Buruli ulcer (BU) surveillance in Benin, 
using the World Health Organization BU02 form. We report 
results of reliable routine data collected on 2,598 new and 
recurrent cases from 2003 through 2005.
B
uruli ulcer (BU), a disease caused by Mycobacterium 
ulcerans, is one of the recently classiﬁ  ed 13 neglected 
tropical diseases (1). It has been reported in >30 countries 
(2). The disease starts as a nonulcerative lesion-like nodule, 
plaque, or edema. Without treatment, these early lesions 
will progress to an ulcer. The disease affects the bone in 
an estimated 13% of patients (3). Treatment often requires 
multiple interventions, including speciﬁ  c  antimicrobial 
agents, surgery, and physiotherapy. Recurrence is high in 
many countries (4,5), and the economic effects on affected 
households, communities, and the health system are con-
siderable (6,7). The exact mode of transmission of the caus-
ative organism is not known. The only known risk factors 
are related to water, particularly the use of unsafe water (8), 
especially that obtained from swamps (9).
We describe Benin’s surveillance system for BU from 
2003 through 2005. The system is based on the use of the 
World Health Organization (WHO) BU02 form.
The Study
The study took place in Benin, West Africa. The BU 
control activities are organized by a National Control Pro-
gramme. Five BU Detection and Treatment Centers (CD-
TUB) are distributed throughout the BU-endemic regions. 
The detection, referral, and follow-up of BU cases rely 
heavily on community-based surveillance teams composed 
of village volunteers and 1 or 2 teachers and supervised by 
health workers from the nearest health facility.
The BU02 form acts as a triple registry. A trained nurse 
registers each case on the form. Each quarter, the complet-
ed ﬁ  rst sheet is sent to the national level. The second sheet 
is sent to the regional level, and the third is kept at the CD-
TUB for local analysis. A training workshop is performed 
annually for the surveillance team. At the national level, 
data are computerized for analysis and mapping, and feed-
back is provided annually at a review meeting with all BU 
management participants.
With the use of this system, from January 1, 2003, 
through December 31, 2005, a total of 2,598 new and re-
current cases were reported and treated in Benin (Tables 
1 and 2). The rates of disease recurrence (6%) were much 
lower than the ﬁ  gures reported in other countries, e.g., 
16% in Ghana (4,5). Euverte found a rate of 3% recur-
rence among 103 patients treated with streptomycin and 
rifampin in Oueme, Benin, in 2005 (6). During the same 
period, the total numbers of leprosy and tuberculosis cases 
were 1,163 and 8,556, respectively. Thus, BU has become 
the second most important mycobacterial disease after tu-
berculosis in some endemic countries, including Benin (3) 
and Ghana (7).
Consistent with other studies (10), our study found that 
51% of the 2,598 cases were in children <15 years of age. 
Cases were equally distributed between male (49.7%) and 
female (50.3%) patients.
Of the total case-patients, 1,644 (63.3%) reported le-
sions on their lower limbs; 524 (20.2%), lesions on their up-
per limbs; 231 (8.9%), lesions on their head, neck, or trunk; 
19 (0.7%), lesions in the perineal region; and 160 (6.2%), 
lesions in multiple areas. The location of a lesion was not 
noted on the BU02 form for 20 (0.8%) case-patients.
Many researchers believe that because legs and arms 
are the most exposed parts of the body they are more likely 
to be injured or to be bitten by an insect that may be as-
sociated with transmission of M. tuberculosis. However, 
why some lesions occur in the perineum, which is the least 
exposed area, remains unclear. In some villages, persons 
take baths in the swamps while carrying out domestic ac-
tivities such as washing clothes or dishes. Lesions around 
the head, neck, and trunk were present in 9% of patients 
and in the perineum in almost 1%. Although these per-
centages are small, managing the technical and cosmetic 
aspects of lesions in the head, neck (11), and perineal re-
gions (12) is difﬁ  cult in Benin, where plastic surgeons are 
not available.
Nonulcerative early lesions (nodule, edema, and 
plaques) occurred in 27% of the total cases. Ulcers and 
mixed forms (an ulcer and some other form of the disease) 
occurred in 72% of the cases, and single ulcerative lesions 
occurred in 54%. The clinical form was not properly re-
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corded for 2% of cases. Our ﬁ  gure of 72% is lower than the 
94% rate reported elsewhere for Benin from 1989 through 
1996 (13). The real challenge in Benin is how to further 
reduce the percentage of ulcers and sustain such surveil-
lance efforts.
Regarding infection involving bone, Debacker et al. 
(3) reported a rate of 13% among 1,700 patients treated at 
CDTUB Zagnanado from 1997 through 2001. However, 
our results showed that bone involvement occurred in 6% 
of cases. Bone infection is a consequence of late disease 
(14). As progress is made in reducing late disease, bone 
lesions should be reduced.
Laboratory conﬁ  rmation of BU is not frequently per-
formed before treatment is begun. Although WHO strongly 
recommends laboratory conﬁ  rmation of cases, in practice 
not all cases require it. Our study shows that 50% of cases 
are conﬁ  rmed by at least 1 laboratory method under routine 
conditions.
The geographic distribution of cases shows that the 
BU-endemic areas are conﬁ  ned to the southern half of 
the country, Most BU-endemic villages occur along the 
Oueme and Couffo Rivers (online Appendix Figure 1, 
available from www.cdc.gov/EID/content/13/9/1374-app
G1.htm, and Appendix Figure 2, available from www.
cdc.gov/EID/content/13/9/1374-appG2.htm).
The Mono Region has the lowest incidence of BU in 
southern Benin. By contrast, the other BU-endemic regions 
are around rivers. This observation cannot be due to insuf-
ﬁ  ciency of reporting because there is a CDTUB in the area 
and surveillance is good (online Appendix Figure 1). Un-
like previous reports from Benin, our results suggest that 
the Oueme Region is now the most endemic for BU, not 
the Zou Region (online Appendix Figure 1). We believe 
that this ﬁ  nding may be due to the active community-level 
detection and antimicrobial drug treatment conducted by 
the new BU center established in the Ouémé/Plateau region 
in April 2004. 
Conclusions
The data provided by Benin’s BU surveillance system 
that used the BU02 form enabled the BU Program in Benin 
to reliably describe the epidemiologic situation, evaluate 
the results of actions, measure the results of the centers, 
and plan future interventions. The collected data are ≈98% 
complete. We conclude that the BU surveillance system is 
useful to the BU Program in Benin. Because the BU02 form 
has 3 parts, data can be submitted from the ﬁ  eld without the 
difﬁ  culties of photocopying the pages of the register or en-
tering the data in a computer, which may be problematic at 
a rural facility level. However, training and supervision of 
health workers are required.
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Table 1. Monthly trends for Buruli ulcer cases, Benin, 2003–2005 
Year Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Total (DR/10,000 
inhabitants)*
2003 59 62 48 49 52 63 79 44 41 93 64 77 731 (1.56) 
2004 86 60 87 57 75 73 77 56 44 77 60 70 822 (1.73) 
2005 72 89 89 91 93 100 77 94 73 88 97 82 1,045 (2.13) 
Total 217 211 224 197 220 236 233 194 158 258 221 229 2,598
*DR, detection rate. 
Table 2. Buruli ulcer cases reported in Benin by region, 2003–2005* 
Region 2003, no. (%)  2004, no. (%)  2005, no. (%)  Total, no. (%) 
Atlantique 171 (23)  171 (21)  263 (25)  605 (23) 
Collines 2 (0) 0 0 2 (0)
Couffo 89 (12)  107 (13)  128 (12)  324 (12) 
Littoral  8 (1)  18 (2)  31 (3)  57 (2) 
Mono 14 (2)  13 (2)  20 (2)  47 (2) 
Oueme 275 (38)  252 (31)  304 (29)  831 (32) 
Plateau 26 (4)  43 (5)  79 (8)  148 (6) 
Zou 124 (17)  201 (24)  198 (19)  523 (20) 
Nigeria  4 (1)  3 (0)  6 (1)  13 (1) 
Togo 2 (0)  2 (0)  1 (0)  5 (0) 
Not specified  16 (2)  12 (1)  15 (1)  43 (2) 
Total 731 (100)  822 (100)  1,045 (100)  2,598 (100) 
*Benin surveillance captures data from the neighboring countries of Nigeria and Togo. DISPATCHES
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